An anti–glypican 3/CD3 bispecific T cell–redirecting antibody for treatment of solid tumors

Entire CD3ε, δ and γ humanized mouse to evaluate human CD3–mediated therapeutics

(2017) Otoya Ueda et al.   Scientific Reports

Harnessing T cells to fight cancer with BiTE®antibody constructs - past developments and future directions

(2016) Matthias Klinger et al.   IMMUNOLOGICAL REVIEWS

Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy

(2016) Maria-Elisabeth Goebeler et al.   LEUKEMIA & LYMPHOMA

Immune Checkpoint Blockade in Cancer Therapy

(2015) Michael A. Postow et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study

(2015) Max S Topp et al.   LANCET ONCOLOGY

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

The future of immune checkpoint therapy

(2015) P. Sharma et al.   SCIENCE

Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies

(2015) Liping L. Sun et al.   Science Translational Medicine

A CD3xCD123 bispecific DART for redirecting host T cells to myelogenous leukemia: Preclinical activity and safety in nonhuman primates

(2015) Gurunadh R. Chichili et al.   Science Translational Medicine

Antitumor Efficacy of a Bispecific Antibody That Targets HER2 and Activates T Cells

(2014) T. T. Junttila et al.   CANCER RESEARCH

Development of T Cells Redirected to Glypican-3 for the Treatment of Hepatocellular Carcinoma

(2014) H. Gao et al.   CLINICAL CANCER RESEARCH

Targeting T cells to tumor cells using bispecific antibodies

(2013) Stanley R Frankel et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Immunogenicity of Murine Solid Tumor Models as a Defining Feature of In Vivo Behavior and Response to Immunotherapy

(2013) Melissa G. Lechner et al.   JOURNAL OF IMMUNOTHERAPY

Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity

(2013) Zenjiro Sampei et al.   PLoS One

Human Regulatory T Cells Kill Tumor Cells through Granzyme-Dependent Cytotoxicity upon Retargeting with a Bispecific Antibody

(2013) B. D. Choi et al.   Cancer Immunology Research

Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms

(2012) Taofic Mounajjed et al.   HUMAN PATHOLOGY

Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens

(2012) M. Friedrich et al.   MOLECULAR CANCER THERAPEUTICS

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data

(2011) Rong Deng et al.   mAbs

Expression of GPC3 protein and its significance in lung squamous cell carcinoma

(2011) Qiang Lin et al.   MEDICAL ONCOLOGY

Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects

(2010) Kannan Gunasekaran et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Glypican-3 expression predicts poor clinical outcome of patients with early-stage clear cell carcinoma of the ovary

(2010) T. Umezu et al.   JOURNAL OF CLINICAL PATHOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells

(2010) Ralf Lutterbuese et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bispecific T-Cell Engaging Antibodies for Cancer Therapy

(2009) P. A. Baeuerle et al.   CANCER RESEARCH

Glypican 3-expressing gastric carcinoma: Distinct subgroup unifying hepatoid, clear-cell, and α-fetoprotein-producing gastric carcinomas

(2009) Tetsuo Ushiku et al.   CANCER SCIENCE

Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA

(2009) Ralf Lutterbuese et al.   JOURNAL OF IMMUNOTHERAPY

Glypican-3 expression in clear cell adenocarcinoma of the ovary

(2009) Daichi Maeda et al.   MODERN PATHOLOGY

Glypican 3 Expression in Human Nonneoplastic, Preneoplastic, and Neoplastic Tissues

(2008) Daniel Baumhoer et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells

(2008) Kiyotaka Nakano et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Anti-Glypican 3 Antibody as a Potential Antitumor Agent for Human Liver Cancer

(2008) T. Ishiguro et al.   CANCER RESEARCH

Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy

(2008) C. H. Chung   ONCOLOGIST

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE